<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559308</url>
  </required_header>
  <id_info>
    <org_study_id>BSU</org_study_id>
    <nct_id>NCT04559308</nct_id>
  </id_info>
  <brief_title>The Effect of Metformin on Breast Cancer Patients</brief_title>
  <official_title>The Effect of Metformin on Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ahram Canadian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several clinical trials have addressed the promising anticancer effect of metformin on the&#xD;
      survival benefits, clinical response, and pathological response of breast cancer patients.&#xD;
&#xD;
      Therefore, this study will assess the anticancer effect of metformin when added to the&#xD;
      neoadjuvant chemotherapy protocol of non-diabetic breast cancer patients. In addition to, the&#xD;
      impact of metformin addition to the neoadjuvant chemotherapy on the quality of life of breast&#xD;
      cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is conducted to assess the effect of metformin addition to the chemotherapy&#xD;
      protocol of non-diabetic breast cancer patients compared to the control group (non-metformin&#xD;
      users) in the neoadjuvant setting. Evaluation of the the clinical benefit rate and the rate&#xD;
      of pathological complete response will be conducted. In addition, a correlation between the&#xD;
      beneficial effect of metformin and the serum concentration of metformin. Also, a comparison&#xD;
      in the quality of life between the metformin group and the control group will be evaluated&#xD;
      using the European Organization for Research and Treatment of Cancer Quality of Life&#xD;
      Questionnaire (EORTC QLQ C30) and (EORTC QLQ BR45) questionnaires will be done.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Actual">September 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is an open-labeled, parallel, randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit rate (Tumor size)</measure>
    <time_frame>8 months</time_frame>
    <description>Tumor size measured in calipers from baseline till the last cycle of neoadjuvant chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response</measure>
    <time_frame>8 months</time_frame>
    <description>The absence of residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with metformin-related adverse events</measure>
    <time_frame>8 months</time_frame>
    <description>Safety and tolerability of conventional anti-diabetic dose of metformin use in breast cancer patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of metformin on the quality of life of breast cancer patients</measure>
    <time_frame>8 months</time_frame>
    <description>A comparison between the metformin arm and the control arm in the change of quality of life from baseline using the European Organization for Research and Treatment of Cancer (EORTC QLQ C30 tools. Scoring of the EORTC QLQ-C30 is performed according to the EORTC scoring manual. After the scoring procedures, all the responses to likert-scale items were linearly transformed to a 0-100 scale. Higher scores for functional scales and the global quality of life scale, indicate better quality of life, while for symptom scales and single items, a higher score indicates a higher severity of the symptoms and worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of metformin on the quality of life of breast cancer patients</measure>
    <time_frame>8 months</time_frame>
    <description>A comparison between the metformin arm and the control arm in the change of quality of life from baseline using the European Organization for Research and Treatment of Cancer (EORTC QLQ BR45).Scoring of the EORTC QLQ-Br45 is performed according to the EORTC scoring manual. After the scoring procedures, all the responses to likert-scale items were linearly transformed to a 0-100 scale. Higher scores for functional scales and the global quality of life scale, indicate better quality of life, while for symptom scales and single items, a higher score indicates a higher severity of the symptoms and worse quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>metformin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel+ Metformin (1000 mg twice daily) followed by surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel followed by surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>first-line anti-diabetic drug</description>
    <arm_group_label>metformin arm</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>First line neoadjuvant chemotherapy protocol</description>
    <arm_group_label>control arm</arm_group_label>
    <arm_group_label>metformin arm</arm_group_label>
    <other_name>Doxorubicin</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-diabetic breast cancer patients, receiving neoadjuvant chemotherapy treatment.&#xD;
&#xD;
          2. Female Age between 18- 65 years.&#xD;
&#xD;
          3. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity reaction to Metformin.&#xD;
&#xD;
          2. Intolerable Metformin GI complaints.&#xD;
&#xD;
          3. Patients at risk of lactic acidosis.&#xD;
&#xD;
          4. Diabetic breast cancer patients.&#xD;
&#xD;
          5. Body Mass Index &lt; 18.5 (underweight breast cancer patients).&#xD;
&#xD;
          6. Renal impairment, eGFR &lt;45 mL/min/1.73 m².&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female breast cancer patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed A El Berry, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Beni-Suef University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hadeer M Ehab, M.Sc.</last_name>
    <phone>01020483388</phone>
    <email>hadeer.ehab7785@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beni-suef university</name>
      <address>
        <city>Banī Suwayf</city>
        <zip>11815</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raghda R Sayed, Ph. D.</last_name>
      <phone>01010647666</phone>
      <email>Raghda.hussien@pharm.bsu.edu.eg</email>
    </contact>
    <investigator>
      <last_name>Hadeer M Ehab, MS.C.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Hadeer Mohamed Ehab</investigator_full_name>
    <investigator_title>Clinical Pharmacy Researcher</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol, safety and efficacy criteria, and statistical analysis.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>1 year</ipd_time_frame>
    <ipd_access_criteria>sent by e-mail</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

